Mainland China: China Tax Incentives Drive Healthy China Initiative Forward
On 13 October 2026, the STA, jointly with the Ministry of Finance and the National Health Commission, issued a policy package detailing tax and fee preferential measures to support the “Healthy China 2030” strategy. The package includes: (1) enhanced super-deduction for R&D expenses in pharmaceutical and medical device manufacturing (increased from 100% to 120%); (2)
Mainland China: China Tax Incentives Drive Healthy China Initiative Forward Read More »
